Business Context and Reporting Period
Company: Anixa Biosciences, Inc. (ANIX)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: January 31, 2025
Business Overview: Anixa is a biotechnology company developing oncology therapies and vaccines. Key programs include a CAR-T therapy for ovarian cancer (via subsidiary Certainty Therapeutics) and vaccines for triple-negative breast cancer (TNBC) and ovarian cancer. The company has no commercial revenue and relies on licensing and potential future partnerships.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,213) | $(3,290) |
| Net Loss Attributable to Common Shareholders | $(3,184) | $(3,255) |
| Net Loss Per Share (Basic & Diluted) | $(0.10) | $(0.10) |
| Cash and Cash Equivalents | $1,053 | $998 |
| Short-term Investments | $16,202 | $18,653 |
| Total Current Assets | $18,686 | $21,362 |
| Total Liabilities | $2,193 | $2,703 |
| Operating Cash Flow | $(2,904) | $(2,309) |
Material Changes vs. Prior Period
- Operating Expenses: Total operating costs decreased by $223,000 to $3.386 million. This was driven by a $426,000 decrease in General and Administrative (G&A) expenses, partially offset by a $203,000 increase in Research and Development (R&D) expenses.
- R&D Expenses: Increased to $1.552 million (from $1.349 million) due to higher outside R&D costs for the breast cancer vaccine program, increased license fees for the ovarian cancer CAR-T therapeutic, and higher employee compensation. These were partially offset by reduced stock-based compensation.
- G&A Expenses: Decreased to $1.834 million (from $2.260 million) primarily due to lower investor relations expenses ($291,000 reduction), reduced legal fees, and lower director stock-based compensation.
- Interest Income: Declined to $173,000 (from $319,000) due to lower interest rates and a reduced balance of short-term investments.
- Liquidity: Total current assets decreased by approximately $2.676 million compared to the prior fiscal year-end (October 31, 2024), reflecting operating cash burn and investment activity.
Outlook, Management Commentary, and Risks
- Clinical Progress:
- CAR-T (Ovarian Cancer): Phase 1 dose-escalation trial is ongoing. Three patients treated in the third dose cohort (10x higher dose) from Nov 2024 to Feb 2025 with good tolerability. Preparing to enroll the 4th dose cohort (30x higher dose).
- Breast Cancer Vaccine: Phase 1 trial data presented at SITC showed antigen-specific immune responses across all dose levels and patient groups. No severe adverse side effects observed. Company anticipates commencing a Phase 2 trial in 2025.
- Liquidity and Capital Resources: Management believes existing cash, cash equivalents, and short-term investments ($17.255 million combined) are sufficient to fund operations for at least the next 12 months. No shares were issued under the at-the-market (ATM) offering program during the quarter, though approximately $97 million remains available for sale.
- Investment Policy: The company holds Bitcoin exchange-traded funds (ETFs) as part of its short-term investments, measured at fair value.
- Risks: No material changes to risk factors from the 2024 10-K. Primary risks include the uncertainty of clinical trial outcomes, the need for future capital raises, and the lack of current revenue generation.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the ~$17.3 million in liquid assets against the current quarterly burn rate of ~$2.9 million in operating cash flow.
- Phase 2 Timeline: Confirm the specific timeline and regulatory requirements for the anticipated Phase 2 breast cancer vaccine trial in 2025.
- Bitcoin Exposure: Review the specific valuation and volatility risk associated with the $10,000 holding in Bitcoin ETFs within short-term investments.
- ATM Program: Monitor the $97 million remaining capacity under the at-the-market offering program as a potential source of dilution if capital needs arise sooner than expected.
- Stock-Based Compensation: Note that non-cash stock-based compensation was $1.055 million for the quarter, significantly reducing the cash burn relative to the reported net loss.